Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same

A composition comprising at least one agent selected from the group consisting of:

• (i) a compound of Formula (I):
• wherein in (I):
• A1 is CH2 or cyclopentane-1,3-diyl;
• n is 0, 1, 2, 3, 4 or 5 if A is CH2, or n is 0, 1, or 2 if A is cyclopentane-1,3-diyl;
• A2 and A3 are both H, or A2 and A3 combine to form a divalent radical selected from the group consisting of methanediyl, ethane-1,2-diyl, or propane-1,3-diyl;
• A4 is CH2, CH(CF3), or CF2;
• R1 and R2 are both H, and R3 is selected from the group consisting of:
• wherein ring A is selected from the group consisting of phenyl, substituted phenyl, pyridinyl, substituted pyridinyl, thiophenyl, substituted thiophenyl, 1H-pyrazole, and 1-(C1-C6) alkyl-1H-pyrazole;
• R4 is nil or (C1-C6)alkyl, wherein if R4 is (C1-C6)alkyl, compound of Formula (I) is a quaternary ammonium salt;
• R5 is (C1-C6)alkyl, substituted (C1-C6)alkyl, phenyl, substituted phenyl, heteroaryl, substituted heteroaryl;
• R6 is H, (C1-C6)alkyl, substituted (C1-C6)alkyl, aryl or substituted aryl;
• and,
• R7 is OH, CH2OH, or C(═O)OR6;
• (ii) a compound of Formula (IX):
• RA—RB (IX),
• wherein:
• RA is a group selected from the group consisting of:
• and,
• RB is a group selected from the group consisting of:
• (iii) a compound of Formula (X):
• wherein R1 is (C1-C8) alkyl, substituted (C1-C8) alkyl, phenyl, substituted phenyl, (C1-C8) cycloalkyl or substituted (C1-C8) cycloalkyl;
• (iv) a compound of Formula (XI):
• wherein
• R is selected from the group consisting of:
• each occurrence of R1 and R4 is independently H, (C1-C6) alkyl, substituted (C1-C6) alkyl, phenyl, substituted phenyl, (C1-C6) cycloalkyl, or substituted (C1-C6) cycloalkyl;
• and,
• R2 and R3 are independently H, (C1-C6) alkyl, substituted (C1-C6) alkyl, phenyl, substituted phenyl, (C1-C6) cycloalkyl, substituted (C1-C6) cycloalkyl, halo, OR4, N(R4)(R4), NO2, or NHAc;
• (v) a compound of Formula (XII):
• wherein
• R is selected from the group consisting of:
• each occurrence of R1, R4 and R5 is independently H, (C1-C6) alkyl, substituted (C1-C6) alkyl, phenyl, substituted phenyl, (C1-C6) cycloalkyl, or substituted (C1-C6) cycloalkyl;
• and,
• R2 and R3 are independently H, (C1-C6) alkyl, substituted (C1-C6) alkyl, phenyl, substituted phenyl, (C1-C6) cycloalkyl, substituted (C1-C6) cycloalkyl, halo, OR4, N(R4)(R4), NO2, or NHAc;
• (vi) a CX3CR1 or fractalkine antibody;
• and
• combinations thereof, and a pharmaceutically acceptable salt thereof.